SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MO...
* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease...
* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patie...
* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients...
* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-bor...
* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience...
* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinica...
* Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients wi...
SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bios...
SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bio...
SEOUL South Korea, May 23, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced on the...
SEOUL, South Korea, May 13, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced that ...
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation ...
SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech compa...
SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announ...
SEOUL, South Korea, Dec. 8, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) release...
SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Expectations are increasing as a Korean bio-tech ...
* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer dru...